



## PERSPECTIVE

# Tetrahydrocannabivarin is Not Tetrahydrocannabinol

Mehdi Haghdoost,<sup>1</sup> Erica N. Peters,<sup>2</sup> Matthew Roberts,<sup>1</sup> and Marcel O. Bonn-Miller<sup>3,\*</sup>

### Abstract

Tetrahydrocannabivarin (THCV) is a phytocannabinoid that is becoming popular across the North American cannabis market. THCV has been reported to reduce blood sugar and act as an appetite suppressant in several independent pre-clinical studies, which has earned it the popular nickname of “diet weed,” despite few human studies of these effects. Additionally, THCV is usually and incorrectly categorized as an intoxicating analogue of tetrahydrocannabinol (THC), which causes confusion among both consumers and regulators. In this article, we examine what is known pre-clinically and clinically about THCV, as well as highlight mechanisms of action, in order to clarify the scientific differences between THCV and THC. THCV, although structurally similar to THC, has distinct pharmacological activity and physiological effects at the doses currently reported in the literature. We highlight areas of opportunity for further THCV research in order to determine the full and appropriate potential for unique health, wellness, and therapeutic applications of this compound.

**Keywords:** THCV; THC; pharmacology; mechanisms of action

### Introduction

Tetrahydrocannabivarin (THCVs) are not tetrahydrocannabinols (THCs) nor are they THC isomers. There is no known biosynthesis pathway in the cannabis plant nor any synthetic chemical reaction that can convert THC to THCV or *vice versa*. In the cannabis plant, tetrahydrocannabivarinic acid (THCVA) originates from varinolic acid. In contrast, olivetolic acid is the origin of tetrahydrocannabinolic acid (THCA) (Fig. 1). After biosynthesis, natural decarboxylation, which can be accelerated with heat,<sup>1</sup> converts the acidic precursors THCVA and THCA to neutral THCV and THC, respectively. The length of the alkyl chain is the main structural difference between these two precursors, which leads to THCV having a smaller molecular weight than THC. The shorter alkyl tail of THCV is meaningful enough to give it distinct chemical, physical, pharmacological, and physiological properties relative to THC and other phytocannabinoids. Despite these

scientifically well-documented differences, THC and THCV are commonly confused with one another. It is, therefore, important to review the relevant scientific reports to provide a clear understanding of what we know to be the difference between these two important phytocannabinoids and to point to the distinct therapeutic potential of each.


One factor possibly contributing to the confusion between THCV and THC is the presence of two common isomers for THCV:  $\Delta 9$ -THCV and  $\Delta 8$ -THCV, similar to the two common isomers for THC,  $\Delta 9$ -THC and  $\Delta 8$ -THC. The  $\Delta 9$  isomer of THCV, a phytocannabinoid first discovered in *Cannabis sativa* by Merkus in 1971<sup>2</sup> is commonly extracted from THCV-dominant cultivars. Conversely, no report mentions the presence of  $\Delta 8$ -THCV in cannabis plants, suggesting that this isomer is a semi-synthetic cannabinoid made by simple acid isomerization of cannabidivarin (CBDV). However, as THCV-dominant *C. sativa*

<sup>1</sup>Nalu Bio Inc, San Francisco, California, USA.

<sup>2</sup>Emerald Mountain Consulting, LLC, Charlottesville, Virginia, USA.


<sup>3</sup>Charlotte's Web, Louisville, Colorado, USA.

\*Address correspondence to: Marcel O. Bonn-Miller, Ph.D., Charlotte's Web, 700 Tech Court, Louisville, CO 80027, USA, E-mail: Marcel.Bonn-Miller@Charlottesweb.com



cultivars are rare, it could also be that no investigation so far has targeted the detection of  $\Delta^8$ -THCV in the plant material. *In vitro* results suggest that  $\Delta^9$ -THCV and  $\Delta^8$ -THCV are both cannabinoid CB1 receptor (CB1R) antagonists, with  $\Delta^8$ -THCV having around  $\sim 2X$  less potency than  $\Delta^9$ -THCV.<sup>3</sup> To our knowledge, human studies to support this difference in potency between THCv isomers are absent. It is noteworthy that the semi-synthetic pathway to  $\Delta^8$ -THCV can result in other THCv isomers such as  $\Delta^9$  (11)-THCV (exo-THCV),  $\Delta^8$ -*iso*-THCV, and  $\Delta^4$  (8)-*iso*-THCV (Fig. 2).<sup>4-6</sup> The

biological activity of these isomers has not been investigated, and owing to the lack of robust analytical methods for their quantitative analysis, their presence in THCv products has not been studied and they are most often generally identified simply as  $\Delta^8$ -THCV. The overlap in terminology and the lack of detailed analysis of various THCv isomers, as described, can lead to confusion regarding the precise composition and potential effects of THCv products, making it challenging for consumers and researchers to understand what specific compounds they are dealing with.



Despite the similarity in the isomers for both THC and THC, *in vitro* receptor binding research supports that THC can be distinguished from THC because of differential CB1R binding behavior. As reviewed by Pertwee,<sup>7</sup> THC is a known potent partial agonist of CB1R, with  $K_i = 5\text{--}80$  nM. Functionality of ligands at CB1R, particularly agonism, is required for creating the cannabis intoxication effect associated with THC.<sup>8</sup> THC has a similar ring structure to THC, but it has a chain length of 3 carbons instead of 5. Although THC can bind to CB1R with high affinity ( $K_i = 22\text{--}75.4$  nM),<sup>9,10</sup> THC is not a CB1R agonist but instead a CB1R antagonist at most biologically relevant dosages. THC antagonism of CB1R has been highlighted in multiple studies. In one of the most recent studies, Walsh and Holmes report that  $\Delta^9$ - and  $\Delta^8$ -THC antagonized the CB1R in an isomer- and ligand-dependent manner.<sup>3</sup>

The reason behind the difference in biological properties between THC and THC is poorly understood. An article by Raich and coworkers suggests that the difference in the functionality of  $\Delta^9$ -THC and  $\Delta^9$ -THC at CB1R originates from variation in binding modes that results in qualitatively different effects depending on the signaling pathway engaged upon receptor activation.<sup>11,32</sup> However, the functionality of THC at CB1R appears to be complex, as some studies have highlighted weak CB1R agonist properties for  $\Delta^9$ -THC. Pertwee suggests that  $\Delta^9$ -THC behaves mainly as a CB1R antagonist but, at higher doses,  $\Delta^9$ -THC acts as a CB1R agonist.<sup>7</sup> Indeed, one study has reported  $\Delta^9$ -THC as a weak partial agonist in the CB1R cAMP inhibition assay.<sup>7</sup> Even weak CB1R agonist activity at high concentrations of  $\Delta^9$ -THC may lead one to expect intoxicating effects in humans at elevated doses; however, accurately predicting such effects from *in vitro* data is challenging owing to the concentration-dependent dual agonist/antagonist behavior of THC.

A few *in silico* studies have also investigated differences in CB1R binding behavior between THC and THC. In a pre-print work at arXiv, Shahbazi and colleagues use molecular docking calculation to show that  $\Delta^9$ -THC binding to CB1R leads to a larger shift in the helices position of the receptor relative to  $\Delta^9$ -THC binding (switch toggle theory).<sup>12</sup> Molecular dynamics and docking studies by Torrent et al. suggest that conformation adopted by the alkyl chain of  $\Delta^9$ -THC and  $\Delta^9$ -THC inside the receptor orthosteric site is likely the reason for their difference in CB1R functionality.<sup>13</sup> Further studies are required to

fully understand the complexity and to validate this theory. It is also still not understood why THC has shown dose-dependent dual agonist/antagonist behavior in some studies.<sup>14,15</sup>

We found very limited scientific data in our attempt to compare the activity of THC and THC at other human receptors. The agonist property of THC (both  $\Delta^8$  and  $\Delta^9$ ) at the CB2 receptor (CB2R) is very well established.<sup>16</sup> THC is reported to have a weaker affinity toward CB2R than THC (reviewed to some extent here<sup>7</sup>). However, similar to CB1R, some studies have reported THC as a potent agonist<sup>17</sup> of CB2R and some as an antagonist.<sup>9</sup> In addition, although both  $\Delta^9$ -THC and  $\Delta^9$ -THC are reported to affect the serotonergic pathway, particularly through the 5-HT<sub>1A</sub> receptor,<sup>18,19</sup> the absence of side-by-side comparison prevents us from drawing a solid conclusion about functional similarities and differences. Finally, THC and THC are similarly active at transient receptor potential (TRP) channels such as TRPV1, TRPV2, TRPV3, TRPV4, TRPA1, and TRPM8 (for a review on this topic, see Muller et al.<sup>20</sup>) with THC being relatively more potent than THC. However, this similarity is hardly of any significance as almost all phytocannabinoids, intoxicating or not, have some activity at TRP receptors.

Given their differential behavior at CB1R, one area of study has focused on the interaction between THC and THC. As a competitive antagonist to CB1R agonists, THC is predicted to act as a competitive antagonist of THC and could inhibit the effects of THC in a dose-dependent fashion in humans and animals. Preliminary scientific data appear to support this hypothesis, at least at specific doses of THC. Pertwee and coworkers reported that at intravenous doses of 0.1–3 mg,  $\Delta^9$ - and  $\Delta^8$ -THC attenuated  $\Delta^9$ -THC-induced anti-nociception (tail-flick test) and hypothermia (rectal temperature) in rats, and  $\Delta^8$ -THC also antagonized  $\Delta^9$ -THC-induced ring immobility.<sup>10</sup> In a recent drug discrimination study,<sup>21</sup>  $\Delta^8$ -THC (10–100 mg/kg, i.p.) did not alter the discriminative stimulus effects of  $\Delta^9$ -THC in male and female rats trained to discriminate  $\Delta^9$ -THC from vehicle. However,  $\Delta^8$ -THC showed a weak signal in modulating the  $\Delta^9$ -THC effect by decreasing response rates (response/sec).<sup>21</sup> In humans, 10 mg of oral pure  $\Delta^9$ -THC administered daily for five days, relative to placebo, inhibited some of the effects of 1 mg intravenous  $\Delta^9$ -THC, such as delayed verbal recall, heart rate, and subjective intensity of effects, although it also increased memory intrusions.<sup>22</sup> The findings of this study may have limited ecological validity, however, as

$\Delta^9$ -THC was administered intravenously rather than *via* inhalation or ingestion. The antagonist effect of THCV isomers does not seem to be limited to THC; pre-clinical studies show that THCV isomers are also capable of antagonizing potent full agonists of CB1R, such as WIN55212.<sup>3</sup> The antagonism effect of  $\Delta^9$ -THCV is, however,  $\sim 3$  and  $\sim 45$  times less than AM-281 and rimonabant, respectively (based on  $IC_{50}$  values).

A few human studies of THCV have provided insights into differences in subjective effects relative to THC. There are two human THCV studies that have demonstrated that 10 mg oral  $\Delta^9$ -THCV may be therapeutic in the treatment of obesity *via* impacts on blood sugar and appetite<sup>23,24</sup> (for a review on potential therapeutic benefits of THCV in the management of obesity and diabetes, see Abioye and colleagues<sup>25</sup>). The appetite-suppressing effect of  $\Delta^9$ -THCV is in stark contrast to  $\Delta^9$ -THC, which is known to increase appetite and craving for food.<sup>26</sup> Additional literature on the effects of THCV in humans is scarce. Early human studies show that the effects of THC and those of THCV at similar doses are quite different. For example, a 10 mg oral dose of  $\Delta^9$ -THC reliably produces an intoxicating effect in humans,<sup>27</sup> which has been used to inform product limits in individual U.S. state markets (e.g., Colorado<sup>28</sup>) and in other countries (e.g., Canada<sup>29</sup>). However, the subjective effects of 10 mg of oral  $\Delta^9$ -THCV, when administered as a single dose (5 mg twice daily)<sup>23</sup> or as a repeated dose over 5 days,<sup>22</sup> have been indistinguishable from those of placebo. It is worth noting that most THCV consumer products contain less than 5 mg THCV. Indeed, much higher oral doses of THCV are needed to produce subjective effects in humans. In a recent placebo-controlled, within-subjects human study on acute doses of  $\Delta^8$ -THCV ranging from 12.5 to 200 mg, 12.5 mg, 25 mg, and 50 mg doses of  $\Delta^8$ -THCV did not demonstrate subjective or cognitive effects typically associated with  $\Delta^9$ -THC consumption.<sup>30</sup> Very slight  $\Delta^9$ -THC-like effects were observed at 100 and 200 mg doses of  $\Delta^8$ -THCV, based in part on a mean observed rating of 0.67 (100 mg  $\Delta^8$ -THCV) and 1.04 (200 mg  $\Delta^8$ -THCV) on the “Marijuana” scale of the Addiction Research Center Inventory (ARCI).<sup>30</sup> As a point of comparison, 3 $\times$  to 5 $\times$  higher ARCI Marijuana scores have been observed after acute dosing of less than 10 mg of  $\Delta^9$ -THC.<sup>31</sup> It is unclear how the effects observed for  $\Delta^8$ -THCV translate to the  $\Delta^9$ -THCV isomer, but findings appear to suggest that the subjective  $\Delta^9$ -THC-like effects produced by high oral doses of  $\Delta^8$ -THCV are of low magnitude.

In conclusion, although close in chemical structure, THCV and THC show distinct pharmacological and physiological properties and are produced through distinct biosynthetic pathways. Several published scientific studies have concluded THCV to be an antagonist of CB1R, whereas it is widely accepted that THC is a potent partial agonist for this same receptor. Early human studies indicate that low oral doses (10 mg) of  $\Delta^9$ -THC elicit an intoxicating effect, whereas similar doses of  $\Delta^9$ -THCV do not. Only at much higher oral doses of  $\Delta^8$ -THCV (100 and 200 mg) have any cannabis-like effect been documented, though at a considerably lower magnitude than has been demonstrated with low doses ( $<10$  mg) of  $\Delta^9$ -THC. Although available evidence points to THCV mainly inhibiting the effects of THC, human pharmacokinetic and pharmacodynamic studies of other doses of THCV with oral doses of THC are needed. Based on this perspective of scientific data, we believe that THCV and THC should not be considered in the same category of psychoactive compounds and should not be grouped together from a regulatory standpoint. We also note the potential difference in antagonist potency of  $\Delta^9$ -THCV and  $\Delta^8$ -THCV, suggesting that one of the next steps in THCV research can be devoted to understanding the difference in dose-effect of these isomers in humans.

#### Author Disclosure Statement

M.H. and M.R. are employees of Nalu Bio. M.H. and E.N.P. are both consultants for Charlotte’s Web and former employees at Canopy Growth Corporation. M.H. is also a former employee of Organigram. M.B.M. is an employee of Charlotte’s Web, Board Member at DeFloria, LLC, and former employee at Canopy Growth Corporation.

#### Funding Information

No funding was received for this article.

#### References

1. Wang M, Wang Y-H, Avula B, et al. Decarboxylation study of acidic cannabinoids: A novel approach using ultra-high-performance supercritical fluid chromatography/photodiode array-mass spectrometry. *Cannabis Cannabinoid Res* 2016;1(1):262–271; doi: 10.1089/can.2016.0020
2. Merkus FWHM. Cannabivarin and tetrahydrocannabivarin, two new constituents of hashish. *Nature* 1971;232(5312):579–580.
3. Walsh KB, Holmes AE. Pharmacology of minor cannabinoids at the cannabinoid cb1 receptor: Isomer- and ligand-dependent antagonism by tetrahydrocannabivarin. *Receptors* 2022;1(1):3–12; doi: 10.3390/receptors1010002
4. Razdan RK, Dalzell HC, Handrick GR. Hashish. A simple one-step synthesis of (-)-delta1-tetrahydrocannabinol (THC) from p-mentha-2,8-dien-1-ol and olivetol. *J Am Chem Soc* 1974;96(18):5860–5865; doi: 10.1021/ja00825a026
5. Bassetti B, Hone CA, Kappe CO. Continuous-flow synthesis of  $\Delta^9$ -tetrahydrocannabinol and  $\Delta^8$ -tetrahydrocannabinol from cannabidiol. *J Org Chem* 2023;88(9):6227–6231; doi: 10.1021/acs.joc.3c00300

6. Banijamali AR, Van Der Schyf CJ, Makriyannis A. Addition and elimination of HCl to tetrahydrocannabinol isomers. A method for the preparation of stereospecifically 2H-labeled cannabinoids. *J Label Compd Radiopharm* 1998;41(2):121–130; doi: 10.1002/(SICI)1099-1344(199802)41:2<121::AID-JLCR55>3.0.CO;2-S
7. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids:  $\Delta$ 9-tetrahydrocannabinol, cannabidiol and  $\Delta$ 9-tetrahydrocannabinol. *Br J Pharmacol* 2008;153(2):199–215; doi: 10.1038/sj.bjp.0707442
8. Pryce G, Baker D. Antidote to cannabinoid intoxication: The CB1 receptor inverse agonist, AM251, reverses hypothermic effects of the CB1 receptor agonist, CB-13, in mice. *Br J Pharmacol* 2017;174(21):3790–3794; doi: 10.1111/bph.13973
9. Thomas A, Stevenson LA, Wease KN, et al. Evidence that the plant cannabinoid  $\Delta$ 9-tetrahydrocannabinol is a cannabinoid CB1 and CB2 receptor antagonist. *Br J Pharmacol* 2005;146(7):917–926; doi: 10.1038/sj.bjp.0706414
10. Pertwee RG, Thomas A, Stevenson LA, et al. The psychoactive plant cannabinoid,  $\Delta$ 9-tetrahydrocannabinol, is antagonized by  $\Delta$ 8- and  $\Delta$ 9-tetrahydrocannabinol in mice in vivo. *Br J Pharmacol* 2007;150(5):586–594; doi: 10.1038/sj.bjp.0707124
11. Raich I, Rivas-Santisteban R, Lillo A, et al. Similarities and differences upon binding of naturally occurring  $\Delta$ 9-tetrahydrocannabinol-derivatives to cannabinoid CB1 and CB2 receptors. *Pharmacol Res* 2021;174:105970; doi: 10.1016/j.phrs.2021.105970
12. Shahbazi F, Meister D, Mohammadzadeh S, et al. A mechanistic model explaining ligand affinity for, and partial agonism of. *Cannabinoid Receptor* 2023;1; doi: 10.26434/chemrxiv-2023-mbr7t
13. Llinas del Torrent C, Raich I, Gonzalez A, et al. The Leu/Val6.51 side chain of cannabinoid receptors regulates the binding mode of the alkyl chain of  $\Delta$ 9-tetrahydrocannabinol. *J Chem Inf Model* 2023;63(18):5927–5935; doi: 10.1021/acs.jcim.3c01054
14. Russo EB, Marcu J. Cannabis pharmacology: The usual suspects and a few promising leads. *Adv Pharmacol* 2017;80:67–134; doi: 10.1016/bs.apha.2017.03.004
15. Zagzoog A, Mohamed KA, Kim HJJ, et al. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from *Cannabis sativa*. *Sci Rep* 2020;10(1):20405; doi: 10.1038/s41598-020-77175-y
16. Bow EW, Rimoldi JM. The structure–function relationships of classical cannabinoids: CB1/CB2 modulation. *Perspect Med Chem* 2016;8:17–39; doi: 10.4137/PMC.S32171
17. Bátkai S, Mukhopadhyay P, Horváth B, et al.  $\Delta$ 8-Tetrahydrocannabinol prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors. *Br J Pharmacol* 2012;165(8):2450–2461; doi: 10.1111/j.1476-5381.2011.01410.x
18. Braidá D, Limonta V, Malabarba L, et al. 5-HT1A receptors are involved in the anxiolytic effect of  $\Delta$ 9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague–Dawley rats. *Eur J Pharmacol* 2007;555(2–3):156–163; doi: 10.1016/j.ejphar.2006.10.038
19. Cascio MG, Zamberletti E, Marini P, et al. The phytocannabinoid,  $\Delta$ 9-tetrahydrocannabinol, can act through 5-HT1A receptors to produce antipsychotic effects. *Br J Pharmacol* 2015;172(5):1305–1318; doi: 10.1111/bph.13000
20. Muller C, Morales P, Reggio PH. Cannabinoid ligands targeting TRP channels. *Front Mol Neurosci* 2018;11:487; doi: 10.3389/fnmol.2018.00487
21. Moore CF, Marusich J, Haghdoost M, et al. Evaluation of the modulatory effects of minor cannabinoids and terpenes on  $\Delta$ 9-tetrahydrocannabinol discrimination in rats. *Cannabis Cannabinoid Res* 2023;8(S1):S42–S50; doi: 10.1089/can.2023.0062
22. Englund A, Atakan Z, Kralj A, et al. The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. *J Psychopharmacol* 2016;30(2):140–151; doi: 10.1177/0269881115615104
23. Jadoon KA, Ratcliffe SH, Barrett DA, et al. Efficacy and safety of cannabidiol and tetrahydrocannabinol on glycemic and lipid parameters in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel group pilot study. *Diabetes Care* 2016;39(10):1777–1786; doi: 10.2337/dc16-0650
24. Tudge L, Williams C, Cowen PJ, et al. Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabinol on food reward and aversion in healthy volunteers. *Int J Neuropsychopharmacol* 2014;18(6):pyu094; doi: 10.1093/ijnp/pyu094
25. Abioye A, Ayodele O, Marinkovic A, et al.  $\Delta$ 9-Tetrahydrocannabinol (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes. *J Cannabis Res* 2020;2(1):6; doi: 10.1186/s42238-020-0016-7
26. Kirkham TC. Cannabinoids and appetite: Food craving and food pleasure. *Int Rev Psychiatry* 2009;21(2):163–171; doi: 10.1080/09540260902782810
27. Spindle TR, Martin EL, Grabenauer M, et al. Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis. *J Psychopharmacol* 2021;35(7):786–803; doi: 10.1177/02698811211021583
28. Parnes JE, Bravo AJ, Conner BT, et al. A burning problem: Cannabis lessons learned from Colorado. *Addict Res Theory* 2018;26(1):3–10; doi: 10.1080/16066359.2017.1315410
29. Pusiak RJ, Cox C, Harris CS. Growing pains: An overview of cannabis quality control and quality assurance in Canada. *Int J Drug Policy* 2021;93:103111; doi: 10.1016/j.drugpo.2021.103111
30. Peters EN, MacNair L, Harrison A, et al. A two-phase, dose-ranging, placebo-controlled study of the safety and preliminary test of acute effects of oral  $\Delta$ 8-tetrahydrocannabinol in healthy participants. *Cannabis Cannabinoid Res* 2023;8(S1):S71–S82; doi: 10.1089/can.2023.0038
31. Wachtel S, ElSohly M, Ross S, et al. Comparison of the subjective effects of  $\Delta$ 9-tetrahydrocannabinol and marijuana in humans. *Psychopharmacology (Berl)* 2002;161(4):331–339; doi: 10.1007/s00213-002-1033-2
32. Haghdoost M, López de los Santos Y, Brunstetter M, et al. Using in silico molecular docking to explain differences in receptor binding behavior of hhc and thcv isomers: revealing new binding. *Pharmaceuticals* 2024;17(5):637; doi: 10.3390/ph17050637

**Cite this article as:** Haghdoost M, Peters EN, Roberts M, Bonn-Miller MO (2025) Tetrahydrocannabinol (THCV) is not tetrahydrocannabinol (THC). *Cannabis and Cannabinoid Research* 10:1, 1–5, DOI: 10.1089/can.2024.0051.

#### Abbreviations Used

- $\Delta$ 4(8)-iso-THCV = Delta-4(8)-iso-tetrahydrocannabinol
- $\Delta$ 8-iso-THCV = Delta-8-iso-tetrahydrocannabinol
- $\Delta$ 8-THC = Delta-8-tetrahydrocannabinol
- $\Delta$ 8-THCV = Delta-8-tetrahydrocannabinol
- $\Delta$ 9-THC = Delta-9-tetrahydrocannabinol
- $\Delta$ 9-THCV = Delta-9-tetrahydrocannabinol
- $\Delta$ 9(11)-THCV = Delta-9(11)-Tetrahydrocannabinol
- ARCI = Addiction Research Center Inventory
- CB1R = Cannabinoid CB1 receptor
- CB2R = Cannabinoid CB2 receptor
- CBDV = Cannabidiol
- IC50 = Half maximal inhibitory concentration
- i.p. = Intraperitoneal
- i.v. = Intravenous
- Ki = Inhibition constant
- THC = Tetrahydrocannabinol
- THCA = Tetrahydrocannabinolic acid
- THCV = Tetrahydrocannabinol
- THCVA = Tetrahydrocannabinolic acid
- TRP = Transient receptor potential
- TRPA1 = Transient receptor potential ankyrin 1
- TRPM8 = Transient receptor potential melastatin 8
- TRPV1 = Transient receptor potential vanilloid 1
- TRPV2 = Transient receptor potential vanilloid 2
- TRPV3 = Transient receptor potential vanilloid 3
- TRPV4 = Transient receptor potential vanilloid 4